Using Cell-Based Assays in the Development of Efficacious Cancer Therapies



Category: Research Services

01/12/2015

 

Presenter:  Dr. Kyla Grimshaw, VP Research Operations, Horizon Discovery 

Personalized medicine has changed the landscape of cancer drug discovery. Tools such as panels of isogenic cell lines, RNAi screening platforms and assays that mimic the tumor environment all contribute to greater understanding of disease and more accurate prediction of patient responses to drugs and drug combinations.

In this webinar, Dr Kyla Grimshaw describes how Horizon Discovery Services can help you to answer key questions, including identification of on-target drug activity, identification of responsive or resistant patient populations, compound profiling and detailed mechanism of action studies, and effects of the tumor micro-environment on tumor growth and drug response (3D assay systems).

Back to top